Superworth

Caris Life Sciences profit margin CAI

Gross, operating and net profit as a share of revenue over the last twelve months, from 2024.

Net margin, 12 months
10.6%
Operating margin, 12 months
15.5%
Net margin on a year earlier
+62.9 pts
Peer median
13.6%

Over the twelve months to Jun 30, 2026, Caris Life Sciences kept 10.6% of its revenue as net profit, with an operating margin of 15.5% and a gross margin of 69.7%.

The median for 10 diagnostics and research stocks of a similar size is 13.6%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY2025−8.4%5.6%66.4%
FY2024−68.4%−62.4%43.4%

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY2610.6%+62.9 pts15.5%
Q1 FY263.7%+64.2 pts11.9%
Q4 FY25−8.4%+60.0 pts5.6%
Q3 FY25−28.8%n/a−12.4%
Q2 FY25−52.3%n/a−32.6%
Q1 FY25−60.4%n/a−49.2%
Q4 FY24−68.4%n/a−62.4%
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a

Against its peers

Companies in Medical - Diagnostics & Research nearest Caris Life Sciences' size, closest first, today.

CompanyProfit margin
CAICaris Life Sciences10.6%
BIOBio-Rad Laboratories8.6%
LNTHLantheus17.7%
BLLNBillionToOne9.5%
RVTYRevvity8.2%
MEDPMedpace17.7%
VCYTVeracyte20.4%
CDNACareDx24.2%
LHLabcorp7.0%
DGXQuest Diagnostics9.2%
MTDMettler-Toledo International21.9%
Peer median13.6%

Where Caris Life Sciences ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Caris Life Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.